KA/EN
Register
Medicines reference
Search
Search
Product

Gabagamma

Favourites

Gabapentin · Wörwag Pharma

2 forms: capsule. In force in Georgia: 2 of 2 (human register).

Controlled substance. For use only by a veterinarian, as the law prescribes.

Forms and doses2 of 2 in force in Georgia

Form Dose Frequency Georgia
300 mg, Capsule No label dose in the reference yet - Georgia Yes, human
In force until 10 Apr 2030
Human (Ministry of Health, RAMA)
In the register: გაბაგამა 300 მგ, კაფსულა
№ რ-043108
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Gabagamma 300 mg, Capsule

hard capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment
6.2/10
Situational / acceptable
vetman assessment

Gabagamma

300 mg, hard capsule, human medicine
Assessed clinical scopeDog · Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment · By mouth
Care settingUsually veterinarian-directed home administration; exact dosing interval, renal adjustment, response target and taper depend on whether the role is pain, seizure adjunct or a single pre-event anxiolytic dose
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043108 · Verified on 16 Oct 2026 Off-label use

Gabapentin can be a useful role-specific adjunct, particularly for feline pre-visit fear, but evidence is uneven across pain and seizure uses and these exact 300/400 mg whole capsules are poorly matched to cats and many small dogs. Define the target outcome, use a measurable renal-adjusted dose, reassess early and taper sustained treatment rather than stopping abruptly.

Regulatory and scientific credibility7.0/10

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Clinical efficacy5.5/10

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Safety and tolerability6.5/10

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

Clinical practicality5.5/10

A whole 300 mg capsule can fit some medium-to-large dogs, is stable and easy to store, but the exact label requires swallowing it whole. It is too coarse for many small-dog starting doses or renal adjustments, and the short canine half-life can require repeated daily administration; a 100 mg or validated compounded form is often more practical.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • These exact 300/400 mg hard capsules must be swallowed whole according to their current labels. Do not treat the capsule as quarter-divisible or divide its powder by eye; use a lower strength or a pharmacy-validated preparation when the prescribed dose is not a whole capsule.
  • Do not substitute a human gabapentin oral liquid or an informal compounded vehicle without checking every excipient. Some liquid formulations may contain xylitol, which can cause severe hypoglycaemia and hepatic injury in dogs.
  • Concurrent opioids, sedatives, anaesthetics or other CNS depressants can increase sedation, ataxia and respiratory depression. Review the full regimen and reduce or monitor according to patient frailty, respiratory disease and procedure plan.
  • Reduce the dose and/or extend the interval in renal impairment. Cats with CKD can have substantially higher gabapentin exposure even at a lower mg/kg dose; excessive or prolonged sedation, weakness or ataxia warrants reassessment.
  • Do not stop sustained gabapentin abruptly, particularly when used for seizure control. Taper under veterinary direction; sudden withdrawal may cause rebound signs, withdrawal syndrome or breakthrough seizures/status epilepticus.
  • Gabapentin is an adjunct, not a substitute for diagnosis, disease-modifying care or proven first-line analgesia/antiepileptic treatment. Do not let transient sedation be mistaken for pain relief or successful anxiety control.
  • Define a role-specific outcome before starting: validated pain/function measures, seizure frequency and interictal interval, or handling/stress response. Reassess early and discontinue gradually if no clinically meaningful benefit is demonstrated.
  • Sedation and ataxia can distort gait, activity, neurological examination and blood-pressure interpretation. Record dose and timing, prevent falls or unsafe jumping, and interpret examination findings in the context of recent gabapentin exposure.
  • Aluminium- or magnesium-containing antacids can reduce gabapentin absorption; separate administration by at least two hours when clinically relevant. Review other antiepileptic and analgesic medicines for additive adverse effects.
  • Safety of these exact human capsules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and select a better characterised alternative when available.
Assessment sources
  1. Gabagamma capsule official SmPC2026
  2. WSAVA pain guideline2023
  3. Cat Friendly gabapentin guide2023
  4. Feline previsit gabapentin RCT2017
  5. Feline fear-aggression gabapentin RCT2021
  6. Feline osteoarthritis gabapentin trial2018
  7. Feline CKD gabapentin study2022
  8. Canine neuropathic pain trial2020
  9. Canine refractory epilepsy study2005
  10. Canine oral gabapentin PK2011
  11. Veterinary gabapentin review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment
5.9/10
Weak evidence support
vetman assessment

Gabagamma

300 mg, hard capsule, human medicine
Assessed clinical scopeCat · Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment · By mouth
Care settingUsually veterinarian-directed home administration; exact dosing interval, renal adjustment, response target and taper depend on whether the role is pain, seizure adjunct or a single pre-event anxiolytic dose
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043108 · Verified on 16 Oct 2026 Off-label use

Gabapentin can be a useful role-specific adjunct, particularly for feline pre-visit fear, but evidence is uneven across pain and seizure uses and these exact 300/400 mg whole capsules are poorly matched to cats and many small dogs. Define the target outcome, use a measurable renal-adjusted dose, reassess early and taper sustained treatment rather than stopping abruptly.

Regulatory and scientific credibility7.0/10

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Clinical efficacy7.5/10

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Safety and tolerability6.0/10

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

Clinical practicality1.0/10

The exact label requires this 300 mg hard capsule to be swallowed whole. That unit exceeds the 50-200 mg total doses studied for most feline pre-visit protocols and greatly exceeds many weight-based chronic-pain increments; it cannot be quartered accurately. A lower-strength capsule or pharmacy-validated xylitol-free compound is normally required.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • These exact 300/400 mg hard capsules must be swallowed whole according to their current labels. Do not treat the capsule as quarter-divisible or divide its powder by eye; use a lower strength or a pharmacy-validated preparation when the prescribed dose is not a whole capsule.
  • Do not substitute a human gabapentin oral liquid or an informal compounded vehicle without checking every excipient. Some liquid formulations may contain xylitol, which can cause severe hypoglycaemia and hepatic injury in dogs.
  • Concurrent opioids, sedatives, anaesthetics or other CNS depressants can increase sedation, ataxia and respiratory depression. Review the full regimen and reduce or monitor according to patient frailty, respiratory disease and procedure plan.
  • Reduce the dose and/or extend the interval in renal impairment. Cats with CKD can have substantially higher gabapentin exposure even at a lower mg/kg dose; excessive or prolonged sedation, weakness or ataxia warrants reassessment.
  • Do not stop sustained gabapentin abruptly, particularly when used for seizure control. Taper under veterinary direction; sudden withdrawal may cause rebound signs, withdrawal syndrome or breakthrough seizures/status epilepticus.
  • Gabapentin is an adjunct, not a substitute for diagnosis, disease-modifying care or proven first-line analgesia/antiepileptic treatment. Do not let transient sedation be mistaken for pain relief or successful anxiety control.
  • Define a role-specific outcome before starting: validated pain/function measures, seizure frequency and interictal interval, or handling/stress response. Reassess early and discontinue gradually if no clinically meaningful benefit is demonstrated.
  • Sedation and ataxia can distort gait, activity, neurological examination and blood-pressure interpretation. Record dose and timing, prevent falls or unsafe jumping, and interpret examination findings in the context of recent gabapentin exposure.
  • Aluminium- or magnesium-containing antacids can reduce gabapentin absorption; separate administration by at least two hours when clinically relevant. Review other antiepileptic and analgesic medicines for additive adverse effects.
  • Safety of these exact human capsules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and select a better characterised alternative when available.
Assessment sources
  1. Gabagamma capsule official SmPC2026
  2. WSAVA pain guideline2023
  3. Cat Friendly gabapentin guide2023
  4. Feline previsit gabapentin RCT2017
  5. Feline fear-aggression gabapentin RCT2021
  6. Feline osteoarthritis gabapentin trial2018
  7. Feline CKD gabapentin study2022
  8. Canine neuropathic pain trial2020
  9. Canine refractory epilepsy study2005
  10. Canine oral gabapentin PK2011
  11. Veterinary gabapentin review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Gabapentin300 mg
Formulation Type
Capsule
Administration route
By mouth
Manufacturer
Wörwag Pharma · Germany
Registration
Georgia Yes, human
In force until 10 Apr 2030
Human (Ministry of Health, RAMA)
In the register: გაბაგამა 300 მგ, კაფსულა
№ რ-043108
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
Yes
Listed under the Georgian narcotics law (Annex 1) or the Minister's Order No. 22/n. The legal text is in Georgian.
Verified on: 16 Oct 2026
400 mg, Capsule No label dose in the reference yet - Georgia Yes, human
In force until 10 Apr 2030
Human (Ministry of Health, RAMA)
In the register: გაბაგამა 400 მგ, კაფსულა
№ რ-043109
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Gabagamma 400 mg, Capsule

hard capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment
6.0/10
Situational / acceptable
vetman assessment

Gabagamma

400 mg, hard capsule, human medicine
Assessed clinical scopeDog · Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment · By mouth
Care settingUsually veterinarian-directed home administration; exact dosing interval, renal adjustment, response target and taper depend on whether the role is pain, seizure adjunct or a single pre-event anxiolytic dose
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043109 · Verified on 16 Oct 2026 Off-label use

Gabapentin can be a useful role-specific adjunct, particularly for feline pre-visit fear, but evidence is uneven across pain and seizure uses and these exact 300/400 mg whole capsules are poorly matched to cats and many small dogs. Define the target outcome, use a measurable renal-adjusted dose, reassess early and taper sustained treatment rather than stopping abruptly.

Regulatory and scientific credibility7.0/10

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Clinical efficacy5.5/10

Canine evidence is mixed and role-dependent. Oral pharmacokinetics support rapid absorption but a short half-life; a small uncontrolled refractory-epilepsy study found benefit in some dogs, while randomized pain studies are limited and have not consistently separated gabapentin from placebo or strong background analgesia. It is therefore an adjunct with a predefined response target, not a default standalone analgesic or anticonvulsant.

Safety and tolerability6.5/10

Sedation and ataxia are the principal dose-limiting veterinary effects; rapid dose escalation, concurrent opioids or other CNS depressants can increase impairment and respiratory risk. Renal elimination, short canine half-life and withdrawal or breakthrough-seizure risk make dose interval, kidney function and gradual discontinuation clinically important. Exact-product long-term safety data in dogs are absent.

Clinical practicality4.5/10

A whole 400 mg capsule may fit selected large-dog regimens but is a coarse unit for titration, small dogs and renal adjustment, and the exact label requires swallowing it whole. Repeated dosing with a short canine half-life increases treatment burden; a lower strength is usually preferable when precise response-guided adjustment is needed.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • These exact 300/400 mg hard capsules must be swallowed whole according to their current labels. Do not treat the capsule as quarter-divisible or divide its powder by eye; use a lower strength or a pharmacy-validated preparation when the prescribed dose is not a whole capsule.
  • Do not substitute a human gabapentin oral liquid or an informal compounded vehicle without checking every excipient. Some liquid formulations may contain xylitol, which can cause severe hypoglycaemia and hepatic injury in dogs.
  • Concurrent opioids, sedatives, anaesthetics or other CNS depressants can increase sedation, ataxia and respiratory depression. Review the full regimen and reduce or monitor according to patient frailty, respiratory disease and procedure plan.
  • Reduce the dose and/or extend the interval in renal impairment. Cats with CKD can have substantially higher gabapentin exposure even at a lower mg/kg dose; excessive or prolonged sedation, weakness or ataxia warrants reassessment.
  • Do not stop sustained gabapentin abruptly, particularly when used for seizure control. Taper under veterinary direction; sudden withdrawal may cause rebound signs, withdrawal syndrome or breakthrough seizures/status epilepticus.
  • Gabapentin is an adjunct, not a substitute for diagnosis, disease-modifying care or proven first-line analgesia/antiepileptic treatment. Do not let transient sedation be mistaken for pain relief or successful anxiety control.
  • Define a role-specific outcome before starting: validated pain/function measures, seizure frequency and interictal interval, or handling/stress response. Reassess early and discontinue gradually if no clinically meaningful benefit is demonstrated.
  • Sedation and ataxia can distort gait, activity, neurological examination and blood-pressure interpretation. Record dose and timing, prevent falls or unsafe jumping, and interpret examination findings in the context of recent gabapentin exposure.
  • Aluminium- or magnesium-containing antacids can reduce gabapentin absorption; separate administration by at least two hours when clinically relevant. Review other antiepileptic and analgesic medicines for additive adverse effects.
  • Safety of these exact human capsules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and select a better characterised alternative when available.
Assessment sources
  1. Gabagamma capsule official SmPC2026
  2. WSAVA pain guideline2023
  3. Cat Friendly gabapentin guide2023
  4. Feline previsit gabapentin RCT2017
  5. Feline fear-aggression gabapentin RCT2021
  6. Feline osteoarthritis gabapentin trial2018
  7. Feline CKD gabapentin study2022
  8. Canine neuropathic pain trial2020
  9. Canine refractory epilepsy study2005
  10. Canine oral gabapentin PK2011
  11. Veterinary gabapentin review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment
5.8/10
Weak evidence support
vetman assessment

Gabagamma

400 mg, hard capsule, human medicine
Assessed clinical scopeCat · Veterinarian-directed oral gabapentin as an adjunct within multimodal management of chronic or neuropathic pain, refractory seizure disorders or situational anxiety, with role-specific diagnosis, dosing and outcome assessment · By mouth
Care settingUsually veterinarian-directed home administration; exact dosing interval, renal adjustment, response target and taper depend on whether the role is pain, seizure adjunct or a single pre-event anxiolytic dose
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043109 · Verified on 16 Oct 2026 Off-label use

Gabapentin can be a useful role-specific adjunct, particularly for feline pre-visit fear, but evidence is uneven across pain and seizure uses and these exact 300/400 mg whole capsules are poorly matched to cats and many small dogs. Define the target outcome, use a measurable renal-adjusted dose, reassess early and taper sustained treatment rather than stopping abruptly.

Regulatory and scientific credibility7.0/10

This exact human hard-capsule family has sourced current registrations in Georgia and EU/EEA, an active current regulator-hosted SmPC and no exact GB or US registration in the checked registers. Veterinary use is off-label and no authorised veterinary product matching these 300/400 mg capsules was located.

Clinical efficacy7.5/10

Feline evidence is strongest for short-term pre-visit fear and stress reduction, supported by several blinded randomized studies, usually with 50-200 mg total doses. A small randomized osteoarthritis study found owner-perceived mobility improvement but lower measured activity and frequent sedation, so chronic analgesic efficacy is less certain; seizure evidence is indirect. Benefit must be judged separately for the intended role.

Safety and tolerability6.0/10

Transient sedation, ataxia, weakness, hypersalivation and occasional vomiting are documented in feline trials and can alter gait and neurological examination. Cats with CKD have substantially higher dose-normalised concentrations, requiring reduction and longer observation. Chronic exposure adds accumulation and withdrawal concerns, and these exact high-strength human capsules have no feline tolerability study.

Clinical practicality0.5/10

The exact label requires this 400 mg hard capsule to be swallowed whole. It is even further from the 50-200 mg total feline pre-visit evidence and from typical weight-based chronic dosing, so the exact presentation is generally unsuitable for accurate feline use without professional reformulation; informal powder division is not acceptable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • These exact 300/400 mg hard capsules must be swallowed whole according to their current labels. Do not treat the capsule as quarter-divisible or divide its powder by eye; use a lower strength or a pharmacy-validated preparation when the prescribed dose is not a whole capsule.
  • Do not substitute a human gabapentin oral liquid or an informal compounded vehicle without checking every excipient. Some liquid formulations may contain xylitol, which can cause severe hypoglycaemia and hepatic injury in dogs.
  • Concurrent opioids, sedatives, anaesthetics or other CNS depressants can increase sedation, ataxia and respiratory depression. Review the full regimen and reduce or monitor according to patient frailty, respiratory disease and procedure plan.
  • Reduce the dose and/or extend the interval in renal impairment. Cats with CKD can have substantially higher gabapentin exposure even at a lower mg/kg dose; excessive or prolonged sedation, weakness or ataxia warrants reassessment.
  • Do not stop sustained gabapentin abruptly, particularly when used for seizure control. Taper under veterinary direction; sudden withdrawal may cause rebound signs, withdrawal syndrome or breakthrough seizures/status epilepticus.
  • Gabapentin is an adjunct, not a substitute for diagnosis, disease-modifying care or proven first-line analgesia/antiepileptic treatment. Do not let transient sedation be mistaken for pain relief or successful anxiety control.
  • Define a role-specific outcome before starting: validated pain/function measures, seizure frequency and interictal interval, or handling/stress response. Reassess early and discontinue gradually if no clinically meaningful benefit is demonstrated.
  • Sedation and ataxia can distort gait, activity, neurological examination and blood-pressure interpretation. Record dose and timing, prevent falls or unsafe jumping, and interpret examination findings in the context of recent gabapentin exposure.
  • Aluminium- or magnesium-containing antacids can reduce gabapentin absorption; separate administration by at least two hours when clinically relevant. Review other antiepileptic and analgesic medicines for additive adverse effects.
  • Safety of these exact human capsules in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Use only after a documented veterinary benefit-risk assessment and select a better characterised alternative when available.
Assessment sources
  1. Gabagamma capsule official SmPC2026
  2. WSAVA pain guideline2023
  3. Cat Friendly gabapentin guide2023
  4. Feline previsit gabapentin RCT2017
  5. Feline fear-aggression gabapentin RCT2021
  6. Feline osteoarthritis gabapentin trial2018
  7. Feline CKD gabapentin study2022
  8. Canine neuropathic pain trial2020
  9. Canine refractory epilepsy study2005
  10. Canine oral gabapentin PK2011
  11. Veterinary gabapentin review2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Gabapentin400 mg
Formulation Type
Capsule
Administration route
By mouth
Manufacturer
Wörwag Pharma · Germany
Registration
Georgia Yes, human
In force until 10 Apr 2030
Human (Ministry of Health, RAMA)
In the register: გაბაგამა 400 მგ, კაფსულა
№ რ-043109
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
Yes
Listed under the Georgian narcotics law (Annex 1) or the Minister's Order No. 22/n. The legal text is in Georgian.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Gabapentin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10–15 mg/kg
off-label
 Dog Neuropathic and Chronic Pain
Analgesia
 By mouth 3 times daily
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Analgesics Used in Animals
MSD/Merck Veterinary Manual, 2024
3–10 mg/kg
off-label
 Cat Neuropathic and Chronic Pain
Analgesia
 By mouth every 8-12 hours
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Analgesics Used in Animals
MSD/Merck Veterinary Manual, 2024
13–29.4 mg/kg
off-label
 Cat Situational Anxiety
Sedation
 By mouth once
Di Cesare et al. 2023
Scientific article
A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied.
Gabapentin: Clinical Use and Pharmacokinetics in Dogs, Cats, and Horses
Animals (Basel), 2023

Known Contraindications

  • Critical
    Known hypersensitivity to gabapentin is a contraindication.
  • Critical (Dog)
    Sugar-free liquid medicines, including oral gabapentin solutions and syrups, often contain xylitol, which is toxic to dogs. Check the excipients before giving a liquid formulation to a dog.
    Sources: MSD Vet Manual
  • Warning
    Gabapentin is eliminated by the kidneys. Reduce or extend the dosing interval in renal impairment according to clinical response and renal function.
  • Caution
    The dose must be tapered down to avoid rebound pain.
    Sources: MSD Vet Manual
  • Caution
    Gabapentin may cause ataxia and sedation in both dogs and cats. Use cautiously in patients in which impaired coordination or excessive sedation poses additional risk.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗